NASDAQ:TPTXTurning Point Therapeutics Stock Price, Forecast & News

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 49.2% and is now trading at $60.47.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Turning Point Therapeutics.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics (NASDAQ:TPTX) released its earnings results on Monday, August, 10th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.07.
View Turning Point Therapeutics' earnings history.

7 equities research analysts have issued 12 month target prices for Turning Point Therapeutics' shares. Their forecasts range from $56.00 to $90.00. On average, they anticipate Turning Point Therapeutics' stock price to reach $73.57 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics.

News stories about TPTX stock have been trending negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Turning Point Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Turning Point Therapeutics.

Turning Point Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,470,000 shares, an increase of 17.1% from the January 15th total of 2,110,000 shares. Based on an average trading volume of 529,900 shares, the days-to-cover ratio is currently 4.7 days. Approximately 10.5% of the company's shares are sold short.
View Turning Point Therapeutics' Short Interest.

Some companies that are related to Turning Point Therapeutics include Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM) and Schrodinger (SDGR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), Opko Health (OPK), AbbVie (ABBV), Boeing (BA), General Motors (GM), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Pfizer (PFE) and Paypal (PYPL).

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Jennison Associates LLC (1.77%), Candriam Luxembourg S.C.A. (0.66%), Emerald Advisers LLC (0.60%), Emerald Mutual Fund Advisers Trust (0.54%), Swiss National Bank (0.21%) and Monashee Investment Management LLC (0.15%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

TPTX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Strs Ohio, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, and Amalgamated Bank.
View insider buying and selling activity for Turning Point Therapeutics.

TPTX stock was bought by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Candriam Luxembourg S.C.A., Monashee Investment Management LLC, Swiss National Bank, Asymmetry Capital Management L.P., Rafferty Asset Management LLC, and Arizona State Retirement System. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $60.47.

Turning Point Therapeutics has a market capitalization of $2.17 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]